Company profile
ELI LILLY & Co
NYSE:LLYBiotechnology: Pharmaceutical Preparations
Drug pipeline (219)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tirzepatide | approved | $14.9BQ2 2026 | 74 | approved |
| INSULIN LISPRO | approved | $2.3BFY 2024 | 65 | approved |
| BARICITINIB | phase2 | $1.9BFY 2024 | 56 | active |
| Abemaciclib | approved | $1.5BQ2 2026 | 56 | approved |
| INSULIN GLARGINE | approved | $1.4BFY 2024 | 154 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2098)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02516046 | phase3 | completed | 2015-09-01 | 2018-06-13 | Avid Radiopharmaceuticals | 18F-AV-1451 Autopsy Study |
| NCT02350634 | phase1 | completed | 2016-11-26 | 2017-06-16 | Avid Radiopharmaceuticals | 18F-AV-1451 High Resolution Autopsy Study |
| NCT02512029 | phase1 | withdrawn | 2015-10-01 | 2017-04-01 | Avid Radiopharmaceuticals | 18F-AV-1451 PET Imaging in TBI |
| NCT02079766 | phase2 | completed | 2014-06-01 | 2015-10-01 | Avid Radiopharmaceuticals | 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy |
| NCT05775601 | — | completed | 2023-02-28 | 2023-04-04 | Avid Radiopharmaceuticals | 18F-LY3950321-01 Biodistribution and Safety Study |
FDA applications (157)
| Application | Approved | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|---|
| NDA 220934 | 2026-04-01 | NDA | ELI LILLY AND CO | ||||
Loading… | |||||||
| NDA 218881 | 2025-09-25 | NDA | ELI LILLY AND CO | ||||
Loading… | |||||||
| BLA 761306 | 2024-09-13 | BLA | Eli Lilly and Company | ||||
Loading… | |||||||
| BLA 761248 | 2024-07-02 | BLA | Eli Lilly and Company | ||||
Loading… | |||||||
| NDA 218160 | 2024-04-10 | NDA | ELI LILLY AND CO | ||||
Loading… | |||||||